CLINICAL TRIALS PROFILE FOR RECOMBIVAX HB
✉ Email this page to a colleague
All Clinical Trials for RECOMBIVAX HB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02057263 ↗ | The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults | Completed | Massachusetts General Hospital | Phase 1 | 2014-04-01 | Vaccines are one of our most effective public health tools but many who need them don't respond well and are not protected. Adjuvants boost immune responses and are commonly included in vaccine preparations. Bisphosphonates are the most commonly prescribed treatment for osteoporosis and may represent a new class of adjuvant. Bisphosphonates are well tolerated with chronic administration and have very few adverse effects. Research suggests that these medications can stimulate the immune system. Bisphosphonates are of special interest in populations with impaired immunity and an inability to amount protective antibody responses following immunizations. We propose a pilot study to evaluate the clinical relevance of this finding in humans. We will study the effect of bisphosphonates on quantitative humoral immune response to hepatitis B vaccine in healthy older volunteers who have not previously received this vaccine. |
| NCT02429583 ↗ | Effects of Persistent Innate Immune Activation on Vaccine Efficacy | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | 2015-05-08 | This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination. We will recruit chronic HCV patients and healthy control patients for HBV vaccination. We will use RNA Sequencing (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all genes, to determine patients' innate immune status, and learn how this innate immune signature is related to HBV vaccine response. We will then explore the mechanisms by which chronic HCV infection affects different immune cells and functions that are known to be important for an effective HBV vaccine response. These studies will enhance our understanding of the immune effects of chronic viral infection, establish factors that determine effective vaccine responses, and help guide vaccination strategies for HCV patients and other individuals with chronic inflammatory disease. |
| NCT02429583 ↗ | Effects of Persistent Innate Immune Activation on Vaccine Efficacy | Terminated | Rockefeller University | Phase 4 | 2015-05-08 | This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination. We will recruit chronic HCV patients and healthy control patients for HBV vaccination. We will use RNA Sequencing (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all genes, to determine patients' innate immune status, and learn how this innate immune signature is related to HBV vaccine response. We will then explore the mechanisms by which chronic HCV infection affects different immune cells and functions that are known to be important for an effective HBV vaccine response. These studies will enhance our understanding of the immune effects of chronic viral infection, establish factors that determine effective vaccine responses, and help guide vaccination strategies for HCV patients and other individuals with chronic inflammatory disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RECOMBIVAX HB
Condition Name
Clinical Trial Locations for RECOMBIVAX HB
Trials by Country
Clinical Trial Progress for RECOMBIVAX HB
Clinical Trial Phase
Clinical Trial Sponsors for RECOMBIVAX HB
Sponsor Name
